Table 3.
AS (n = 46) | Ps-SpA (n = 51) | uSpA (n = 43) | P | Total (n = 140) | |
---|---|---|---|---|---|
Peripheral arthritis, n (%) | 9 (20) | 26 (51)* | 9 (21)** | <0.001 | 44 (31) |
Enthesitis, n (%) | 11 (24) | 7 (14) | 11 (26) | 0.49 | 29 (21) |
Uveitis, n (%) | 4 (9) | 1 (2) | 3 (7) | 0.33 | 8 (6) |
Clinic form (axial-mixed), n(%) | 44 (96) | 15 (29)* | 31 (72)*,** | <0.001 | 90 (64) |
BASFI | 2.8 ± 2.6 | 2.8 ± 2.5 | 2.4 ± 2.3 | 0.74 | 2.7 ± 2.4 |
Chest expansion, cm | 4.9 ± 2.6 | 4.0 ± 1.5 | 5.1 ± 2.0 | 0.06 | 4.7 ± 2.2 |
Schober modified, cm | 4.2 ± 2.6 | 4.6 ± 1.8 | 5.8 ± 3.3* | 0.016 | 4.9 ± 2.7 |
Occiput-to-wall distance, cm | 1.7 ± 3.5 | 1.0 ± 2.4 | 0.6 ± 1.8 | 0.16 | 1.1 ± 2.7 |
Finger-to-floor distance, cm | 13.6 ± 12 | 12.8 ± 12.5 | 8.2 ± 9.0* | 0.06 | 11.6 ± 11.4 |
Cervical rotation 20°–70°, n (%) | 10 (22) | 9 (18) | 3 (7) | 0.13 | 22 (16) |
Results are expressed as the mean ± s.d., unless otherwise specified. Significance obtained by the chi-square test for qualitative variables and analysis of variance for quantitative variables (Games–Howell as post hoc test). *Significant differences (P < 0.05) vs AS. **Significant differences (P < 0.05) vs Ps-SpA.